Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Oxaliplatin, and Radiation in Pancreatic Cancer
NCT00456599Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2007
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in pancreatic cancer (PC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Disease Free Survival at 2 years. Started Apr 2007; status: completed.
02
Drugs
oxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00456599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456599.